Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2022.2793
Abstract: This post hoc analysis of the randomized clinical trial, Study of LY3002813 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ), investigates if amyloid reduction from donanemab treatment is associated with slowing of tau pathology and… read more here.
Keywords: reduction donanemab; donanemab treatment; amyloid reduction; pathology ... See more keywords